Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorMirra, Serena
dc.contributor.authorGavaldà-Navarro, Aleix
dc.contributor.authorManso, Yasmina
dc.contributor.authorSerrat, Román
dc.contributor.authorSalcedo Allende, Maria Teresa
dc.contributor.authorMinguez Rosique, Beatriz
dc.contributor.authorHiguera Urbano, Monica
dc.contributor.authorBalibrea, José M.
dc.date.accessioned2021-11-19T08:46:50Z
dc.date.available2021-11-19T08:46:50Z
dc.date.issued2021-03-05
dc.identifier.citationMirra S, Gavaldà-Navarro A, Manso Y, Higuera M, Serrat R, Salcedo MT, et al. ARMCX3 Mediates Susceptibility to Hepatic Tumorigenesis Promoted by Dietary Lipotoxicity. Cancers. 2021 Mar 5;13(5):1110.
dc.identifier.issn2072-6694
dc.identifier.urihttps://hdl.handle.net/11351/6567
dc.descriptionLipotoxicity; Obesity
dc.description.abstractARMCX3 is encoded by a member of the Armcx gene family and is known to be involved in nervous system development and function. We found that ARMCX3 is markedly upregulated in mouse liver in response to high lipid availability, and that hepatic ARMCX3 is upregulated in patients with NAFLD and hepatocellular carcinoma (HCC). Mice were subjected to ARMCX3 invalidation (inducible ARMCX3 knockout) and then exposed to a high-fat diet and diethylnitrosamine-induced hepatocarcinogenesis. The effects of experimental ARMCX3 knockdown or overexpression in HCC cell lines were also analyzed. ARMCX3 invalidation protected mice against high-fat-diet-induced NAFLD and chemically induced hepatocarcinogenesis. ARMCX3 invalidation promoted apoptotic cell death and macrophage infiltration in livers of diethylnitrosamine-treated mice maintained on a high-fat diet. ARMCX3 downregulation reduced the viability, clonality and migration of HCC cell lines, whereas ARMCX3 overexpression caused the reciprocal effects. SOX9 was found to mediate the effects of ARMCX3 in hepatic cells, with the SOX9 interaction required for the effects of ARMCX3 on hepatic cell proliferation. In conclusion, ARMCX3 is identified as a novel molecular actor in liver physiopathology and carcinogenesis. ARMCX3 downregulation appears to protect against hepatocarcinogenesis, especially under conditions of high dietary lipid-mediated hepatic insult.
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofseriesCancers;13(5)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectFetge - Càncer - Tractament
dc.subject.meshCarcinoma, Hepatocellular
dc.subject.mesh/chemically induced
dc.titleARMCX3 Mediates Susceptibility to Hepatic Tumorigenesis Promoted by Dietary Lipotoxicity
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3390/cancers13051110
dc.subject.decscarcinoma hepatocelular
dc.subject.decs/inducido químicamente
dc.relation.publishversionhttps://doi.org/10.3390/cancers13051110
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Mirra S, Manso Y, Serrat R] Department of Cell Biology, Physiology and Immunology, University of Barcelona, 08007 Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, 28029 Madrid, Spain. [Gavaldà-Navarro A] Department of Biochemistry and Molecular Biomedicine and Institute of Biomedicine, University of Barcelona, 08028 Barcelona, Spain. Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain. [Higuera M] Grup de Recerca en Malalties Hepàtiques, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Salcedo MT] Servei de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Balibrea JM] Unitat de Cirurgia Endocrina, Metabòlica i Bariàtrica, Servei de Cirurgia General, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Mínguez B] Grup de Recerca en Malalties Hepàtiques, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, 28029 Madrid, Spain. Unitat del Fetge, Servei de Medicina Interna, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain
dc.identifier.pmid33807672
dc.identifier.wos000627947800001
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2013-2016/SAF2017-85722-R
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2017-2020/PID2019-106764RB-C21
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record